Anixa Biosciences, Inc.
ANIXNASDAQHealthcare● Active
$2.46
$-0.02(-0.81%)
Market Cap$82478531
P/E Ratio—
52W High$5.46
52W Low$2.44
Anixa Biosciences, Inc. (ANIX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANIX · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 9, 2026EPS Actual
-$0.08
Est. -$0.09 · +11.1%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 9, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ANIX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 11, 2026 | -$0.09 | — | — | — | — | — |
| ◌ Q2 FY2026 | Jun 10, 2026 | -$0.10 | — | — | — | — | — |
| ▲ Q1 FY2026 | Mar 9, 2026 | -$0.09 | -$0.08 | +11.1% | — | — | — |
| ▼ Q1 FY2026 | Jan 12, 2026 | -$0.09 | -$0.09 | -2.3% | — | — | — |
| ▲ Q3 FY2025 | Sep 10, 2025 | -$0.10 | -$0.07 | +30.0% | — | — | — |
| ▲ Q2 FY2025 | May 28, 2025 | -$0.10 | -$0.09 | +10.0% | — | — | — |
| — Q1 FY2025 | Mar 11, 2025 | -$0.10 | -$0.10 | +0.0% | — | — | — |
| ▲ Q1 FY2025 | Jan 10, 2025 | -$0.11 | -$0.09 | +18.2% | — | — | — |
Q3 FY2026
Sep 11, 2026
EPS Actual
—
EPS Est.
-$0.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 10, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 9, 2026Beat
EPS Actual
-$0.08
EPS Est.
-$0.09
EPS Surpr.
+11.1%
Revenue
—
Q1 FY2026
Jan 12, 2026Miss
EPS Actual
-$0.09
EPS Est.
-$0.09
EPS Surpr.
-2.3%
Revenue
—
Q3 FY2025
Sep 10, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.10
EPS Surpr.
+30.0%
Revenue
—
Q2 FY2025
May 28, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.10
EPS Surpr.
+10.0%
Revenue
—
Q1 FY2025
Mar 11, 2025
EPS Actual
-$0.10
EPS Est.
-$0.10
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Jan 10, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.11
EPS Surpr.
+18.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q3 FY2028 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q2 FY2028 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q1 FY2028 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q4 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q3 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 9, 2026 | +11.1% | $2.85 | $2.98 | +4.56% |
| ▼ Q1 FY2026 | Jan 12, 2026 | -2.3% | $3.38 | $3.16 | -6.51% |
| ▲ Q3 FY2025 | Sep 10, 2025 | +30.0% | $2.98 | $3.02 | +1.34% |
| ▲ Q2 FY2025 | May 28, 2025 | +10.0% | $2.50 | $2.54 | +1.60% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +0.0% | $2.63 | $2.66 | +1.14% |
| ▲ Q1 FY2025 | Jan 10, 2025 | +18.2% | $2.25 | $2.25 | +0.00% |
| ▲ Q3 FY2024 | Sep 6, 2024 | +9.1% | $3.36 | $3.21 | -4.46% |
| ▲ Q2 FY2024 | Jun 4, 2024 | +9.1% | $2.57 | $2.55 | -0.78% |
Q1 FY2026+4.56%
Report Date
Mar 9, 2026
EPS Beat/Miss
+11.1%
Price Before
$2.85
Price After
$2.98
Q1 FY2026-6.51%
Report Date
Jan 12, 2026
EPS Beat/Miss
-2.3%
Price Before
$3.38
Price After
$3.16
Q3 FY2025+1.34%
Report Date
Sep 10, 2025
EPS Beat/Miss
+30.0%
Price Before
$2.98
Price After
$3.02
Q2 FY2025+1.60%
Report Date
May 28, 2025
EPS Beat/Miss
+10.0%
Price Before
$2.50
Price After
$2.54
Q1 FY2025+1.14%
Report Date
Mar 11, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.63
Price After
$2.66
Q1 FY2025+0.00%
Report Date
Jan 10, 2025
EPS Beat/Miss
+18.2%
Price Before
$2.25
Price After
$2.25
Q3 FY2024-4.46%
Report Date
Sep 6, 2024
EPS Beat/Miss
+9.1%
Price Before
$3.36
Price After
$3.21
Q2 FY2024-0.78%
Report Date
Jun 4, 2024
EPS Beat/Miss
+9.1%
Price Before
$2.57
Price After
$2.55
Avg Beat Reaction+0.49%
Avg Miss Reaction-6.51%
Beat Rate7 / 8 quarters
Largest Move-6.51% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANIX ends December
Anixa Biosciences, Inc. (ANIX) most recently reported earnings on March 9, 2026 for Q1 FY2026, posting EPS of $-0.08 — beating the analyst consensus of $-0.09 by +11.1%. The next ANIX earnings date is expected around September 1, 2026.
Each quarter, investors track ANIX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANIX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANIX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANIX earnings · 5 questionsAnixa Biosciences, Inc.'s next earnings report is expected around September 1, 2026. ANIX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANIX historically reports after market close (AMC).
ANIX earnings datewhen is ANIX earningsANIX next earnings datewhen does ANIX report earningsANIX earnings calendar
▸ Source: FMP · Anixa Biosciences, Inc. SEC filings · US GAAP · Anixa Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026